Editing Amgen (section)

==Timeline==
{{prose|date=October 2024}}
*1984: In June, Amgen and Kirin formed a joint venture giving Kirin the rights to Epogen in Japan.<ref>{{cite news |title=Kirin and Amgen Hormone Venture |url=https://www.nytimes.com/1984/06/15/business/kirin-and-amgen-hormone-venture.html |work=The New York Times |date=15 June 1984 |agency=Reuters |access-date=10 August 2022}}</ref><ref>{{Cite web |date=31 October 2017 |title=Japan's Kirin cashes out of Amgen drug joint venture |url=https://www.reuters.com/article/idUSKBN1D00YO/ |access-date=22 November 2024 |website=Reuters}}</ref>
*2002:  In July, Amgen acquired Immunex, the developer of Enbrel (etanercept).<ref>{{cite news |last1=Pollack |first1=Andrew |title=Amgen Reports Its Takeover Of Immunex |url=https://www.nytimes.com/2002/07/17/business/amgen-reports-its-takeover-of-immunex.html |access-date=10 August 2022 |work=The New York Times |date=17 July 2002}}</ref>
*2004:  Also, Amgen acquired Tularik, another biotechnology company, expanding the company's research and development pipeline.<ref>{{cite news |last1=Gellene |first1=Denise |title=Amgen to Buy Rival Tularik |url=https://www.latimes.com/archives/la-xpm-2004-mar-30-fi-amgen30-story.html |access-date=10 August 2022 |work=Los Angeles Times |date=30 March 2004}}</ref><ref>{{cite web |title=Amgen buys remaining 79% of Tularik for $1.3B to boost R&D pipeline |url=https://www.thepharmaletter.com/article/amgen-buys-remaining-79-of-tularik-for-1-3b-to-boost-r-d-pipeline |website=The Pharma Letter |date=4 April 2004 |access-date=10 August 2022}}</ref>
*2006: In April, Amgen acquired Abgenix, the developer of Vectibix ([[panitumumab]]), a treatment developed for certain patients with metastatic [[colorectal cancer]].<ref>{{cite news |last1=Pollack |first1=Andrew |title=Amgen to Buy Abgenix, Getting Complete Control of New Colon Cancer Drug |url=https://www.nytimes.com/2005/12/15/business/amgen-to-buy-abgenix-getting-complete-control-of-new-colon-cancer.html |work=The New York Times |date=15 December 2005 |access-date=10 August 2022}}</ref><ref>{{Cite web |title=Amgen Completes Acquisition of Abgenix |url=https://www.technologynetworks.com/genomics/news/amgen-completes-acquisition-of-abgenix-186294 |access-date=2025-01-27 |website=Genomics Research from Technology Networks |language=en}}</ref>
* 2010: On June 6, 2010, Amgen received [[Food and Drug Administration|FDA]] approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.<ref>{{cite web |url=http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125320&DrugName=PROLIA&ActiveIngred=DENOSUMAB&SponsorApplicant=AMGEN&ProductMktStatus=1&goto=Search.Label_ApprovalHistory |title=Drugs@FDA: FDA Approved Drug Products }}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref> In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.<ref>{{cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125320s0000lbl.pdf |title=www.accessdata.fda.gov }}</ref> In November 2010 the [[Food and Drug Administration|FDA]] approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.<ref>{{cite web |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm |archive-url=https://web.archive.org/web/20101121233928/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm234346.htm |url-status=dead |archive-date=November 21, 2010 |title=FDA approves Xgeva to help prevent cancer-related bone injury |website=[[Food and Drug Administration]] }}</ref> The clinical trials primarily enrolled patients with breast or prostate cancer.
*2011: In May, Amgen acquired BioVex,<ref>{{cite news |last1=Timmerman |first1=Luke |title=Xconomy: Amgen to Acquire BioVex for Up To $1B, to Obtain Cancer-Killing Virus Therapy |url=https://xconomy.com/boston/2011/01/24/amgen-to-acquire-biovex-for-up-to-1b-to-obtain-cancer-killing-virus-therapy/ |work=Xconomy |date=24 January 2011 |language=en |access-date=10 August 2022}}</ref><ref>{{Cite web |last=Brown |first=Steven E.F. |date=24 January 2011 |title=Amgen buying BioVex for $425 million |url=https://www.bizjournals.com/sanfrancisco/news/2011/01/24/amgen-buying-biovex-for-425-million.html |access-date=2024-10-10 |website=San Francisco Business Times}}</ref> developer of Imlygic ([[talimogene laherparepvec]]).<ref>{{cite news |last1=Dangi-Garimella |first1=Surabhi |title=Cost Questions Will Follow the Approval of Amgen's Oncolytic Viral Treatment, Imlygic |url=https://www.ajmc.com/view/cost-questions-will-follow-the-approval-of-amgens-oncolytic-viral-treatment-imlygic |access-date=10 August 2022 |work=AJMC |date=28 October 2015 |language=en}}</ref> In December, Amgen and [[Watson Pharmaceuticals]] announced a collaboration to develop and commercialize several [[biosimilar]] medicines worldwide.<ref>{{cite news |last1=Pollack |first1=Andrew |title=Amgen Plans to Team Up With Watson on Generics |url=https://www.nytimes.com/2011/12/20/health/research/amgen-and-watson-to-work-together-on-generic-drugs.html?_r=1 |work=The New York Times |date=20 December 2011 |access-date=10 August 2022}}</ref><ref>{{Cite web |date=19 December 2011 |title=Amgen and Watson strike $400M cancer biosimilars pact |url=https://www.fiercebiotech.com/r-d/updated-amgen-and-watson-strike-400m-cancer-biosimilars-pact |access-date=10 October 2024 |website=Fierce Biotech}}</ref>
*2012: Amgen acquired Micromet, a company focused on [[Bi-specific T-cell engager|BiTE]] technology.<ref>{{cite news |date=26 January 2012 |title=Amgen to buy Micromet for $1.2 billion |url=https://www.reuters.com/article/us-micromet-amgen/amgen-to-buy-micromet-for-1-2-billion-idUSTRE80P0X920120126 |access-date=10 August 2022 |work=Reuters |language=en}}</ref><ref>{{Cite web |date=31 January 2012 |title=Amgen Agrees to Pay 1.16 Billion for Micromet and Its Oncology Drugs |url=https://news.bloomberglaw.com/pharma-and-life-sciences/amgen-agrees-to-pay-116-billion-for-micromet-and-its-oncology-drugs |access-date=10 October 2024 |website=Bloomberg Law}}</ref>
* 2013: Lawmakers inserted text into the fiscal cliff bill that would allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million<ref>{{cite news|last=Lipton|first=Eric|title=Fiscal Footnote: Big Senate Gift to Drug Maker|url=https://www.nytimes.com/2013/01/20/us/medicare-pricing-delay-is-political-win-for-amgen-drug-maker.html?pagewanted=all|work=[[The New York Times]]|access-date=2 February 2013|date=19 January 2013}}</ref> but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.<ref>{{cite news |url=https://www.huffingtonpost.com/jon-entine/after-congressional-budge_b_2759676.html |title=Jon Entine: New York Times Mum After Congressional Budget Office Rebukes Bungled Amgen/Medicare Investigation |work= Huffington Post|date=26 February 2013}}</ref><ref>{{cite web|url=http://www.nephrologynews.com/articles/109331-cbo-analysis-shows-keeping-oral-drugs-out-of-esrd-bundle-could-save-money |archive-url=https://web.archive.org/web/20130605171126/http://www.nephrologynews.com/articles/109331-cbo-analysis-shows-keeping-oral-drugs-out-of-esrd-bundle-could-save-money |url-status=dead |archive-date=2013-06-05 |title=CBO analysis shows keeping oral drugs out of ESRD bundle could save money &#124; Nephrology News & Issues }}</ref>  In May, Kevin Sharer retired, and Robert Bradway, formerly Amgen's president and chief operating officer, became CEO.<ref>{{cite news |title=Amgen appoints CEO Robert Bradway to chair of board |url=https://www.pmlive.com/pharma_appointments/amgen_appoints_ceo_robert_bradway_to_chair_of_board_456016 |access-date=10 August 2022 |work=PMLive |date=17 December 2012 |language=en}}</ref> In June, Amgen acquired Turkish company Mustafa Nevzat Pharmaceuticals, expanding Amgen's presence in Turkey and nearby areas.<ref>{{cite news |last1=Writer |first1=GEN Staff |title=Amgen Ponies Up $700M for Turkey's Mustafa Nevzat |url=https://www.genengnews.com/news/amgen-ponies-up-700m-for-turkeys-mustafa-nevzat/ |access-date=10 August 2022 |work=GEN - Genetic Engineering and Biotechnology News |date=25 April 2012}}</ref> In July, Amgen acquired KAI Pharmaceuticals, developer of Parsabiv ([[etelcalcetide]]).<ref>{{cite news |title=Amgen to Pick Up Peptide Drug Firm KAI Pharmaceuticals for $315M |url=https://www.genengnews.com/news/amgen-to-pick-up-peptide-drug-firm-kai-pharmaceuticals-for-315m/ |work=GEN - Genetic Engineering and Biotechnology News |date=10 April 2012}}</ref><ref>{{cite news |last1=Taylor |first1=Phil |title=Amgen's chronic kidney disease drug Parsabiv cleared in US |url=https://www.pmlive.com/pharma_news/amgens_chronic_kidney_disease_drug_parsabiv_cleared_in_us_1185993 |access-date=11 August 2022 |work=PMLive |date=8 February 2017 |language=en}}</ref> Amgen acquired Iceland-based [[DeCODE genetics|deCODE Genetics]] in December.<ref>{{cite news |title=Amgen Buys deCODE Genetics for $415M |url=https://www.genengnews.com/news/amgen-buys-decode-genetics-for-415m/ |work=GEN - Genetic Engineering and Biotechnology News |date=10 December 2012}}</ref>
*2013: In October, Amgen acquired [[Onyx Pharmaceuticals]], developer of Kyprolis ([[carfilzomib]]).<ref>{{cite news |last1=Wright |first1=Rob |title=Amgen's Acquisition Of Onyx Pharmaceuticals — Through The Eyes Of Tony Coles |url=https://www.lifescienceleader.com/doc/amgen-s-acquisition-of-onyx-pharmaceuticals-through-the-eyes-of-tony-coles-0001 |work=Life Science Leader |date=27 Aug 2018 |access-date=11 August 2022}}</ref>
*2015: In March, the company announced it would license its Phase II candidate drug [[AMG 714]] to developer [[Celimmune]] who plan to develop the anti-IL-15 [[monoclonal antibody]] for treatment against diet nonresponsive [[celiac disease]] and refractory celiac disease.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/celimmune-licenses-amgen-s-amg-714-for-celiac-disease/81250980/|title=GEN - News Highlights:Celimmune Licenses Amgen's AMG 714 for Celiac Disease|work=GEN}}</ref>
*2015: Repatha ([[evolocumab]]) was approved by the FDA in August.<ref>{{cite news |last1=Kolata |first1=Gina |title=F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class |url=https://www.nytimes.com/2015/08/28/health/fda-approves-another-in-a-new-class-of-cholesterol-drugs.html |work=The New York Times |date=27 August 2015 |access-date=11 August 2022}}</ref> In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.<ref name="genengnews.com">{{cite web|url=http://www.genengnews.com/gen-news-highlights/for-up-to-1-55b-amgen-acquires-dezima-pharma/81251735/|title=For Up to $1.55B, Amgen Acquires Dezima Pharma|work=GEN|date=16 September 2015}}</ref><ref>{{Cite web |date=16 September 2015 |title=Amgen to buy Dezima Pharma for $300 million in cash |url=https://www.reuters.com/article/idUSKCN0RG1SL/ |access-date=22 November 2024 |website=Reuters}}</ref> The same day the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programmes. As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.<ref>{{cite news|url=http://www.fiercebiotech.com/story/amgen-bets-17b-xencors-antibody-technology/2015-09-16|title=Amgen bets up to $1.7B on Xencor's antibody technology|work=FierceBiotech|date=16 September 2015 }}</ref><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/amgen-xencor-to-partner-on-cancer-immunotherapy-inflammation-drugs/81251734/|title=Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs|work=GEN|date=16 September 2015}}</ref> In October, the FDA approved Imlygic.<ref>{{cite web |last1=Tontonoz |first1=Matthew |title=T-VEC is First FDA-Approved Oncolytic Virus Therapy |url=https://www.cancerresearch.org/en-us/blog/october-2015/fda-approves-first-in-new-class-of-immunotherapies |website=Cancer Research Institute |language=en |access-date=11 August 2022}}</ref>
*2016: In September, the company announced it would purchase the rights to [[Boehringer Ingelheim]]s Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of [[multiple myeloma]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/amgen-buys-rights-to-myeloma-bite-immunotherapy-from-boehringer-ingelheim/81253166/|title=Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN|date=September 2016}}</ref> Also in September, the FDA approved Amjevita ([[adalimumab]]-atto).<ref name="Staton">{{cite news |last1=Staton |first1=Tracy |title=Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market |url=https://www.fiercepharma.com/pharma/amgen-s-humira-biosim-amjevita-passes-fda-milestone-long-road-to-market |work=Fierce Pharma |date=23 September 2016 |language=en |access-date=11 August 2022}}</ref>
*2017: The FDA approved Parsabiv in February<ref>{{cite news |last1=Bell |first1=Jacob |title=Amgen secures FDA approval for hormone drug |url=https://www.biopharmadive.com/news/amgen-fda-approval-parsabiv/435760/ |work=BioPharma Dive |access-date=11 August 2022 |date=8 February 2017}}</ref> and Mvasi ([[bevacizumab]]-awwb) in September.<ref name="Mvasi approval">{{cite web |title=FDA approves bevacizumab biosimilar Mvasi |url=https://www.gabionline.net/biosimilars/news/FDA-approves-bevacizumab-biosimilar-Mvasi |website=GaBI Online |language=en |date=22 September 2017 |access-date=11 August 2022}}</ref>
*2018:Amgen began constructing a next-generation [[biomanufacturing]] plant at its [[West Greenwich, Rhode Island]], campus in July.<ref>{{cite web |title=Amgen's New Bio-manufacturing Plant, Rhode Island, US |url=https://www.pharmaceutical-technology.com/projects/amgens-next-generation-bio-manufacturing-plant-rhode-island/ |website=Pharmaceutical Technology |date=10 August 2018 |access-date=11 August 2022}}</ref>
*2019: In January, Evenity ([[romosozumab]]) received approval in Japan,<ref>{{cite web |title=Evenity gets first ever approval, in Japan |url=https://www.thepharmaletter.com/article/evenity-gets-first-ever-approval-in-japan |website=The Pharma Letter |access-date=11 August 2022 |date=9 January 2019}}</ref><ref>{{cite news |last1=Taylor |first1=Phil |title=Amgen gets first OK for Evenity in Japan as FDA panel looms |url=https://www.fiercebiotech.com/biotech/amgen-gets-first-ok-for-evenity-japan-as-fda-panel-looms |access-date=11 August 2022 |work=Fierce Biotech |date=9 January 2019 |language=en}}</ref> followed by FDA approval in April.<ref>{{cite news |last1=Liu |first1=Angus |title=Amgen bone drug Evenity finally wins its FDA green light, but there's a catch |url=https://www.fiercepharma.com/pharma/amgen-s-bone-drug-evenity-approved-by-fda-expected-caveat |work=Fierce Pharma |date=10 April 2019 |language=en |access-date=11 August 2022}}</ref> In June, Kanjinti ([[trastuzumab]]-anns) was approved by the FDA.<ref name="Kanjinti approval">{{cite web |title=FDA Approves Amgen's Trastuzumab Biosimilar, Kanjinti |url=https://www.centerforbiosimilars.com/view/fda-approves-amgens-trastuzumab-biosimilar-kanjinti |website=The Center For Biosimilars |language=en |date=13 June 2019 |access-date=11 August 2022}}</ref> Amgen announced it would acquire Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to enhance its drug discovery capabilities.<ref>{{cite news|url=https://uk.reuters.com/article/us-nuevolution-m-a-amgen-idUKKCN1SS0OC|archive-url=https://web.archive.org/web/20190522135225/https://uk.reuters.com/article/us-nuevolution-m-a-amgen-idUKKCN1SS0OC|url-status=dead|archive-date=May 22, 2019|title=Amgen to buy Copenhagen-based Nuevolution for $167 million|newspaper=Reuters|date=22 May 2019|via=uk.reuters.com}}</ref> In August the company announced it would acquire the [[Otezla]] drug programme from [[Celgene]] for $13.4 billion, as part of Celgene and [[Bristol-Myers Squibb]]s merger deal.<ref>{{Cite web|url=https://www.biospace.com/article/releases/amgen-to-acquire-otezla-for-13-4-billion-in-cash-or-approximately-11-2-billion-net-of-anticipated-future-cash-tax-benefits/?s=79|title = Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits| date=26 August 2019 }}</ref><ref>{{Cite news|url=https://uk.reuters.com/article/us-bristol-myers-divestiture-amgen/celgene-to-sell-psoriasis-drug-otezla-for-13-4-billion-to-amgen-idUKKCN1VG102|archive-url=https://web.archive.org/web/20190826111601/https://uk.reuters.com/article/us-bristol-myers-divestiture-amgen/celgene-to-sell-psoriasis-drug-otezla-for-13-4-billion-to-amgen-idUKKCN1VG102|url-status=dead|archive-date=August 26, 2019|title = Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion|newspaper = Reuters|date = 26 August 2019}}</ref> In October, Amgen announced it would be acquiring a 20.5% stake in the [[Beijing]]-based BeiGene for $2.7 billion.<ref>{{Cite web|url=https://www.statnews.com/2019/10/31/amgen-acquires-stake-in-beigene-to-expand-cancer-drug-business-to-china/|title=Amgen acquires stake in BeiGene to grow cancer drug business to China|date=31 October 2019}}</ref> In November, Amgen awarded a $2 million grant to the [[CDC Foundation]] to launch the latter's EmPOWERED Health Program, promoting patient engagement in decision making for their cancer treatment.<ref>{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December, the FDA approved Avsola ([[infliximab]]-axxq).<ref>{{cite news |title=FDA approves Avsola, fourth Remicade biosimilar |url=https://www.healio.com/news/rheumatology/20191206/fda-approves-avsola-fourth-remicade-biosimilar |work=www.healio.com |date=6 Dec 2019 |language=en |access-date=11 August 2022}}</ref>
*2020: In April, Amgen established Amgen K.K. as the company's wholly-owned affiliate in Japan.<ref>{{cite news |title=BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan |url=https://www.reuters.com/article/brief-amgen-establishes-wholly-owned-aff/brief-amgen-establishes-wholly-owned-affiliate-in-japan-idUSFWN2BO1OX |work=Reuters |date=1 April 2020 |language=en |access-date=11 August 2022}}</ref><ref>{{cite news |last1=Liu |first1=Angus |title=Amgen wades deeper into Asia with full control of an Astellas Japanese JV |url=https://www.fiercepharma.com/pharma-asia/amgen-wades-deeper-into-asia-by-assuming-full-control-astellas-japanese-jv |access-date=11 August 2022 |work=Fierce Pharma |date=23 January 2020 |language=en}}</ref> Amgen announced in July that the [[United States Court of Appeals for the Federal Circuit]] had upheld the validity of two Amgen patents that described and claimed Enbrel and methods for making it. The appellate court affirmed an August 2019 decision by the [[United States District Court for the District of New Jersey]] and rejected [[Sandoz]]'s attempt to invalidate the patents on Enbrel.<ref>{{cite news |title=Amgen defeats Novartis appeal over arthritis drug Enbrel's patents |url=https://www.reuters.com/article/us-amgen-novartis-enbrel/amgen-defeats-novartis-appeal-over-arthritis-drug-enbrels-patents-idUSKBN2426EG |work=Reuters |date=1 July 2020 |language=en |access-date=11 August 2022}}</ref> Amgen joined the [[Dow Jones Industrial Average]] on August 24, 2020.<ref>{{cite news |last1=Stevens |first1=Pippa |title=Salesforce, Amgen and Honeywell added to Dow in major shake-up to the average |url=https://www.cnbc.com/2020/08/24/salesforce-amgen-and-honeywell-added-to-dow-in-major-shakeup-to-the-average.html |work=CNBC |date=24 August 2020 |language=en |access-date=11 August 2022}}</ref> In September, Amgen and [[Eli Lilly and Company]] announced a global manufacturing collaboration for [[COVID-19]] antibody therapies.<ref>{{cite news |last1=Blankenship |first1=Kyle |title=Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails |url=https://www.fiercepharma.com/manufacturing/eli-lilly-amgen-join-forces-to-scale-production-covid-19-antibody-cocktails |access-date=11 August 2022 |work=Fierce Pharma |date=17 September 2020 |language=en}}</ref> On December 10, Amgen announced that it joined OneTen, a coalition of large employers that aims to hire and advance one million black Americans over the next ten years.<ref>{{cite news |last1=Manfredi |first1=Lucas |title=CEOs are driving an initiative to hire, train 1M Black workers over next 10 years |url=https://www.foxbusiness.com/economy/oneten-aims-to-hire-1-million-black-workers-over-next-10-years |work=FOXBusiness |date=18 January 2021 |access-date=11 August 2022}}</ref> Later that month, the FDA approved Riabni ([[rituximab]]-arrx), a biosimilar to Rituxan.<ref name="Riabni approval">{{cite news |title=FDA Approves Riabni, Third Biosimilar to Rituxan |url=https://www.clinicaloncology.com/FDA-Watch/Article/12-20/FDA-Approves-Riabni-Third-Biosimilar-to-Rituxan/61514 |access-date=20 September 2022 |work=Clinical Oncology News |date=18 December 2020}}</ref>
*2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, [[bemarituzumab]], for $1.9 billion.<ref>{{Cite web |title=Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash | date=4 March 2021 |url=https://www.biospace.com/article/releases/amgen-to-acquire-five-prime-therapeutics-for-1-9-billion-in-cash/?s=79}}</ref><ref>{{Cite news |date=4 March 2021 |title=Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market |newspaper=Reuters |url=https://www.reuters.com/article/us-five-prime-m-a-amgen/amgen-adds-gastric-cancer-drug-candidate-in-1-9-billion-five-prime-therapeutics-deal-idUSKBN2AW1PT}}</ref><ref>{{Cite web |date=2021-03-19 |title=How Amgen Acquired Five Prime for $1.9 Billion, Beating Out a Dozen Others |url=https://www.biospace.com/how-amgen-acquired-five-prime-for-1-9-billion-beating-out-a-dozen-others |access-date=2024-12-06 |website=BioSpace |language=en-US}}</ref> In the same month, Amgen acquired Rodeo Therapeutics for $720 million.<ref>{{Cite web |title=In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million | date=31 March 2021 |url=https://www.biospace.com/article/amgen-to-buy-rodeo-therapeutics-in-721-million-deal/?s=79}}</ref><ref>{{Cite web |date=2021-03-19 |title=How Amgen Acquired Five Prime for $1.9 Billion, Beating Out a Dozen Others |url=https://www.biospace.com/how-amgen-acquired-five-prime-for-1-9-billion-beating-out-a-dozen-others |access-date=2024-09-11 |website=BioSpace |language=en-US}}</ref> The FDA approved Amgen's [[Sotorasib|Lumakras]] in May for treatment of patients with KRAS-G12C-mutated non-small cell lung cancer.<ref name="Lumakras approval">{{cite news |author=ASCO Post Staff |date=June 25, 2021 |title=FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC |publisher=ASCO Post |url=https://ascopost.com/issues/june-25-2021/fda-approves-sotorasib-for-kras-g12c-mutated-nsclc/ |access-date=March 4, 2022}}</ref> In June, Amgen and [[Kyowa Kirin]] announced joint plans to develop and commercialize a treatment for [[atopic dermatitis]].<ref>{{cite news |last1=Idrus |first1=Amirah Al |date=1 June 2021 |title=Amgen reunites with longtime partner Kyowa Kirin in $400M dermatitis deal |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-reunites-longtime-partner-kyowa-kirin-400m-dermatitis-deal |access-date=20 September 2022}}</ref> In July, Amgen acquired Teneobio for $900 million.<ref>{{Cite web |last=Priyan |first=Vishnu |date=2021-10-20 |title=Amgen concludes acquisition of biotech company Teneobio for $2.5bn |url=https://www.pharmaceutical-technology.com/news/amgen-teneobio-acquisition/ |access-date=2024-09-11 |website=Pharmaceutical Technology |language=en-US}}</ref> In October, Amgen and Neumora Therapeutics announced a research and development collaboration focused on novel precision therapies for certain brain diseases.<ref>{{cite news |last1=Taylor |first1=Nick Paul |date=7 October 2021 |title=Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/meet-neumora-arch-s-500m-amgen-partnered-play-for-targeted-future-neuroscience-r-d |access-date=20 September 2022}}</ref><ref>{{cite news |date=7 October 2021 |title=Amgen to invest $100 million in SoftBank-backed Neumora |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-invest-100-million-softbank-backed-neumora-2021-10-07/ |access-date=20 September 2022}}</ref> Amgen began construction on a new biomanufacturing plant in [[New Albany, Ohio]], in November.<ref>{{cite news |date=8 November 2021 |title=Amgen breaks ground on new biomanufacturing facility in Ohio, US |work=NS Healthcare |url=https://www.ns-healthcare.com/news/amgen-new-biomanufacturing-facility-in-us/ |access-date=20 September 2022}}</ref> In December, the FDA approved Amgen and AstraZeneca's Tezspire ([[tezepelumab]]) for severe [[asthma]].<ref name="Dunleavy">{{cite news |last1=Dunleavy |first1=Kevin |date=20 December 2021 |title=Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspire |language=en |work=Fierce Pharma |url=https://www.fiercepharma.com/pharma/amgen-astrazeneca-win-nod-for-tezspire-severe-asthma-drug-has-blockbuster-potential-analyst |access-date=20 September 2022}}</ref> The FDA also approved Amgen's Otezla for adults with plaque [[psoriasis]] of any severity level.<ref>{{cite news |date=20 December 2021 |title=U.S. FDA approves expanded use of Amgen's psoriasis drug |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/fda-approves-expanded-use-amgens-psoriasis-drug-2021-12-20/ |access-date=20 September 2022}}</ref>
*2022: In January, Amgen announced a research collaboration with Generate Biomedicines across multiple modalities and several therapeutic areas for up to $1.9 billion.<ref>{{cite news |last1=Armstrong |first1=Annalee |date=6 January 2022 |title=Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-chooses-generate-for-1-9b-biobucks-deal-to-churn-out-up-to-10-multi-modality-drug |access-date=23 September 2022}}</ref><ref>{{cite news |last1=Philippidis |first1=Alex |date=6 January 2022 |title=Amgen, Generate Launch Up-to-$1.9B Protein Therapeutics Collaboration |work=GEN - Genetic Engineering and Biotechnology News |url=https://www.genengnews.com/topics/drug-discovery/therapeutics/protein-therapeutics/amgen-generate-launch-up-to-1-9b-protein-therapeutics-collaboration/ |access-date=23 September 2022}}</ref> The company also launched a multi-target collaboration with [[Arrakis Therapeutics]] to identify novel targeted RNA degrader therapeutics.<ref>{{cite news |last1=Armstrong |first1=Annalee |date=11 January 2022 |title=JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-teams-up-arrakis-to-destroy-disease-causing-rna-75m-research-deal |access-date=23 September 2022}}</ref><ref>{{cite news |last1=Pagliarulo |first1=Ned |date=11 January 2022 |title=Amgen partners with Arrakis to develop drugs aimed at RNA |work=BioPharma Dive |url=https://www.biopharmadive.com/news/amgen-arrakis-rna-degrader-small-molecule/616997/ |access-date=23 September 2022}}</ref> The next month, Amgen entered a multi-year collaboration with Plexium to discover novel targeted protein degradation therapies.<ref>{{cite news |last1=Shasteen |first1=Hayley |date=3 February 2022 |title=Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact |work=BioSpace |url=https://www.biospace.com/article/amgen-and-plexium-ink-500m-targeted-protein-degradation-therapies-pact/ |access-date=23 September 2022}}</ref><ref>{{cite news |last1=LaHucik |first1=Kyle |date=3 February 2022 |title=Amgen enters hot protein degradation field with $500M biobucks deal with Plexium |language=en |work=Fierce Biotech |url=https://www.fiercebiotech.com/biotech/amgen-lines-up-500m-biobucks-deal-plexium-for-protein-degradation-therapies |access-date=23 September 2022}}</ref> Also in February, Amgen issued its first [[green bond]] to fund various environmentally friendly initiatives across the company.<ref>{{cite news |last1=Pequeño IV |first1=Antonio |date=23 February 2022 |title=Amgen Issues 'Green Bond' |work=San Fernando Valley Business Journal |url=https://www.sfvbj.com/news/weekly-news/amgen-issues-green-bond/ |access-date=23 September 2022}}</ref><ref>{{cite news |last1=Mutua |first1=David Caleb |date=29 March 2022 |title=Amgen Mulls More Green Bonds After 'Robust Interest' in Debut |work=www.bloomberg.com |url=https://www.bloomberg.com/news/articles/2022-03-29/amgen-mulls-more-green-bonds-after-robust-interest-in-debut |access-date=23 September 2022}}</ref> The company broke ground on a new manufacturing facility in [[Holly Springs, North Carolina]], in March.<ref>{{cite web |last1=Parker |first1=Jason |title=Amgen expects new Holly Springs plant to be 'a permanent home' |url=https://wraltechwire.com/2022/03/07/amgen-expects-new-holly-springs-plant-to-be-a-permanent-home/ |website=WRAL TechWire |access-date=11 July 2023 |date=7 March 2022}}</ref><ref>{{cite news |last1=Sterling |first1=John |date=11 March 2022 |title=Amgen Breaks Ground on NC Biomanufacturing Facility |work=GEN - Genetic Engineering and Biotechnology News |url=https://www.genengnews.com/topics/bioprocessing/amgen-breaks-ground-on-nc-biomanufacturing-facility/ |access-date=23 September 2022}}</ref> In August, the company agreed to acquire ChemoCentryx for $3.7&nbsp;billion in an all-cash deal.<ref>{{Cite web |last=Priyan |first=Vishnu |date=2022-08-05 |title=Amgen to acquire biopharma firm ChemoCentryx for $3.7bn |url=https://www.pharmaceutical-technology.com/news/amgen-acquire-biopharma-chemocentryx/ |access-date=2024-09-11 |website=Pharmaceutical Technology |language=en-US}}</ref> ChemoCentryx is the maker of [[Tavneos]]—a drug treatment for rare diseases called anti-neutrophil cytoplasmic autoantibody-associated [[vasculitis]]—which was approved last year.<ref>{{cite news |url=https://www.wsj.com/articles/amgen-to-buy-chemocentryx-for-3-7-billion-11659614401 |title=Amgen to Buy ChemoCentryx for $3.7 Billion |date=4 August 2022 |work=[[The Wall Street Journal]] |last=Walker |first=Joseph |url-access=limited |archive-url=https://archive.today/20220804170316/https://www.wsj.com/amp/articles/amgen-to-buy-chemocentryx-for-3-7-billion-11659614401 |archive-date=4 August 2022 |url-status=live}}</ref> In December, the company announced it would acquire [[Horizon Therapeutics]] for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments.<ref>{{cite news | url=https://www.reuters.com/markets/deals/amgen-set-buy-biotech-firm-horizon-26-bln-valuation-bloomberg-news-2022-12-12/ | title=Amgen dives deeper into rare disease drugs with $27.8 BLN Horizon deal | newspaper=Reuters | date=12 December 2022 | last1=Mishra | first1=Manas | last2=Satija | first2=Bhanvi }}</ref> 
*2023: Amgen completed the acquisition of [[Horizon Therapeutics]] in October 2023.<ref>{{Cite news |url=https://www.reuters.com/markets/deals/amgen-completes-278-bln-horizon-deal-2023-10-06/ |title=Amgen completes $27.8 billion Horizon deal |date=6 October 2023 |work=Reuters}}</ref> In December, announced plans to use artificial intelligence in partnership with Amazon Web Services to help discover and create medicines.<ref name=":1">{{Cite web |date=2023-12-01 |title=Amgen forges ahead with generative AI to expedite advanced therapies |url=https://ventureburn.com/2023/12/amgen-forges-ahead-with-generative-ai-to-expedite-advanced-therapies/ |access-date=2023-12-07 |website=Ventureburn |language=en-ZA}}</ref> Amgen will use Amazon's SageMaker machine learning service to help with the  manufacturing process.<ref name=":1" />  That same month, it was confirmed that Amgen would sponsor the 2024 Irish Open as the title sponsor.<ref>{{Cite web |date=2023-12-14 |title=Irish Open sponsor name change after Amgen's takeover of Horizon |url=https://www.independent.ie/sport/golf/irish-open-sponsor-name-change-after-amgens-takeover-of-horizon/a2119441670.html |access-date=2024-12-06 |website=Irish Independent |language=en}}</ref>